Answers are grounded in this paper and cite their sources.
Both authors: Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE *See also p. 337. Dr. Cawcutt received funding from Becton, Dickinson and Company. Dr. Kalil has disclosed that he was an investigator for the National Institutes of Health Adaptive COVID-19 Treatment Trial.
No takes yet. Share an insight, caveat, or question.
Cawcutt et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: